A few years ago, during a taxi ride, the driver described to me how a pig had transformed his life. A childhood with dogs taught him what to expect from animals, yet he was unprepared for the pig he ...

Women gather at a neighborhood square in Lilongwe, Malawi, on June 8 Women gather at a neighborhood square in Lilongwe, Malawi, on June 8Zafer Goder—Anadolu/Getty Images In Malawi, one in three women ...

Exclamation marks, ellipses and ‘haha’ can’t fix our growing inability to communicate. By Nitsuh Abebe “How Many Exclamation Points Are Too Many in an Email? A Psychologist Weighs In.” A psychologist!

It’s January, which means I am slogging through Dry January after the festive overindulgence. This year, however, I am doing so with a book in hand: Charles Knowles’s Why We Drink Too Much, a guide ...

This is a review of Truth: What It Is, How To Find It & Why It Still Matters. by Michael Shermer, forthcoming from Johns Hopkins University Press. Amidst claims of “fake news,” “alternative facts,” ...

The percentage of teachers who are using artificial intelligence-driven tools in their classrooms nearly doubled between 2023 and 2025, according to data from the EdWeek Research Center. In 2023, a ...

Researchers came to Dr. Chris Knowles’ school in England when he was 18 years old to run an experiment. They wanted to see which novice drinkers responded the most to alcohol and who would later go on ...

Chances are you’ve experienced the phenomenon of goosebumps. Maybe you were moved by a beautiful song or felt an intense rush of emotions. Or perhaps you were just cold. Goosebumps may seem like a ...

Right or (as it turns out) wrong, I wasn’t a sprinkle-your-first-name-into-conversation kind of guy. I’m not hugely self-assured, and saying the other person’s name felt forced. Or awkward. Or ...

Nearly six years after the pandemic prompted a new remote work era, return to office battles are back in the news, from Instagram chief Adam Mosseri saying he wants everyone in the office five days a ...

The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing. 10 stocks we like better ...